Caris Life Sciences (CAI)
Market Price (11/9/2026): $25.15 | Market Cap: $7.2 BilSector: Health Care | Industry: Biotechnology
Caris Life Sciences (CAI)
Market Price (11/9/2026): $25.15Market Cap: $7.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 61% Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -129% | Key risksCAI key risks include [1] its history of persistent net losses and high cash burn, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 61% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -129% |
| Key risksCAI key risks include [1] its history of persistent net losses and high cash burn, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 11/6/2026
Caris Life Sciences (CAI) stock has gained about 60% since 7/31/2026 because of the following key factors:
1. Caris Life Sciences reported strong fiscal Q3 2026 financial results that exceeded analyst expectations and raised its full-year guidance.
The company announced total revenue of $275.4 million for the quarter ended September 30, 2026, marking a 27% increase year-over-year and surpassing consensus estimates of approximately $251 million to $255 million. Additionally, GAAP earnings per share (EPS) for the quarter were $0.05, beating analyst expectations of $0.03. Following these results, Caris Life Sciences increased its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, representing 28% to 29% growth over 2025.
2. The company demonstrated robust growth in its core molecular profiling services and clinical case volume.
Molecular profiling services revenue, a key driver, increased by 27% year-over-year to $262.7 million for fiscal Q3 2026. Caris Life Sciences also reported a significant 21% year-over-year increase in clinical case volume, completing approximately 61,500 cases during the quarter. This represented an acceleration in case growth for the second consecutive quarter, indicating strong demand and execution in its primary business segments.
Show more
Caris Life Sciences (CAI) stock has gained about 60% since 7/31/2026 because of the following key factors:
1. Caris Life Sciences reported strong fiscal Q3 2026 financial results that exceeded analyst expectations and raised its full-year guidance.
The company announced total revenue of $275.4 million for the quarter ended September 30, 2026, marking a 27% increase year-over-year and surpassing consensus estimates of approximately $251 million to $255 million. Additionally, GAAP earnings per share (EPS) for the quarter were $0.05, beating analyst expectations of $0.03. Following these results, Caris Life Sciences increased its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, representing 28% to 29% growth over 2025.
2. The company demonstrated robust growth in its core molecular profiling services and clinical case volume.
Molecular profiling services revenue, a key driver, increased by 27% year-over-year to $262.7 million for fiscal Q3 2026. Caris Life Sciences also reported a significant 21% year-over-year increase in clinical case volume, completing approximately 61,500 cases during the quarter. This represented an acceleration in case growth for the second consecutive quarter, indicating strong demand and execution in its primary business segments.
Show more
Updated on 11/6/2026
Caris Life Sciences (CAI) stock has gained about 60% since 7/31/2026 because of the following key factors:
1. Caris Life Sciences reported strong fiscal Q3 2026 financial results that exceeded analyst expectations and raised its full-year guidance.
The company announced total revenue of $275.4 million for the quarter ended September 30, 2026, marking a 27% increase year-over-year and surpassing consensus estimates of approximately $251 million to $255 million. Additionally, GAAP earnings per share (EPS) for the quarter were $0.05, beating analyst expectations of $0.03. Following these results, Caris Life Sciences increased its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, representing 28% to 29% growth over 2025.
2. The company demonstrated robust growth in its core molecular profiling services and clinical case volume.
Molecular profiling services revenue, a key driver, increased by 27% year-over-year to $262.7 million for fiscal Q3 2026. Caris Life Sciences also reported a significant 21% year-over-year increase in clinical case volume, completing approximately 61,500 cases during the quarter. This represented an acceleration in case growth for the second consecutive quarter, indicating strong demand and execution in its primary business segments.
3. Analyst sentiment improved significantly, leading to multiple price target upgrades.
Following the strong fiscal Q3 2026 performance, several prominent research firms raised their price targets for Caris Life Sciences. Citigroup, for example, increased its price target to $36 from $28 while maintaining a "Buy" rating. Other analysts, including UBS Group and BTIG Research, set or reaffirmed price targets as high as $38.00. The consensus rating for the stock became "Moderate Buy," with an average price target in the range of $30.82 to $38.00.
4. Strategic product launches and pipeline advancements fueled investor optimism for future growth.
Caris Life Sciences launched Caris Assure® Therapy Response Monitoring, an expansion of its blood-based platform for serially monitoring treatment response. Furthermore, the company announced the targeted launch of Caris Confirm, a Whole Genome, tumor-informed assay for minimal residual disease (MRD), before the end of 2026. Finalized results from the Achieve 1 Study for Caris Detect™, its multi-cancer early detection test, also highlighted the superiority of its Whole Genome Sequencing approach, further strengthening its product pipeline.
Show less
Caris Life Sciences (CAI) stock has gained about 60% since 7/31/2026 because of the following key factors:
1. Caris Life Sciences reported strong fiscal Q3 2026 financial results that exceeded analyst expectations and raised its full-year guidance.
The company announced total revenue of $275.4 million for the quarter ended September 30, 2026, marking a 27% increase year-over-year and surpassing consensus estimates of approximately $251 million to $255 million. Additionally, GAAP earnings per share (EPS) for the quarter were $0.05, beating analyst expectations of $0.03. Following these results, Caris Life Sciences increased its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, representing 28% to 29% growth over 2025.
2. The company demonstrated robust growth in its core molecular profiling services and clinical case volume.
Molecular profiling services revenue, a key driver, increased by 27% year-over-year to $262.7 million for fiscal Q3 2026. Caris Life Sciences also reported a significant 21% year-over-year increase in clinical case volume, completing approximately 61,500 cases during the quarter. This represented an acceleration in case growth for the second consecutive quarter, indicating strong demand and execution in its primary business segments.
3. Analyst sentiment improved significantly, leading to multiple price target upgrades.
Following the strong fiscal Q3 2026 performance, several prominent research firms raised their price targets for Caris Life Sciences. Citigroup, for example, increased its price target to $36 from $28 while maintaining a "Buy" rating. Other analysts, including UBS Group and BTIG Research, set or reaffirmed price targets as high as $38.00. The consensus rating for the stock became "Moderate Buy," with an average price target in the range of $30.82 to $38.00.
4. Strategic product launches and pipeline advancements fueled investor optimism for future growth.
Caris Life Sciences launched Caris Assure® Therapy Response Monitoring, an expansion of its blood-based platform for serially monitoring treatment response. Furthermore, the company announced the targeted launch of Caris Confirm, a Whole Genome, tumor-informed assay for minimal residual disease (MRD), before the end of 2026. Finalized results from the Achieve 1 Study for Caris Detect™, its multi-cancer early detection test, also highlighted the superiority of its Whole Genome Sequencing approach, further strengthening its product pipeline.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 61.0% change in CAI stock from 7/31/2026 to 11/8/2026 was primarily driven by a 144.7% change in the company's Net Income Margin (%).| (LTM values as of) | 7312026 | 11082026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.67 | 25.23 | 61.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 907 | 1,048 | 15.5% |
| Net Income Margin (%) | 3.7% | 9.2% | 144.7% |
| P/E Multiple | 130.3 | 74.6 | -42.8% |
| Shares Outstanding (Mil) | 283 | 284 | -0.5% |
| Cumulative Contribution | 61.0% |
Market Drivers
7/31/2026 to 11/8/2026| Return | Correlation | |
|---|---|---|
| CAI | 61.0% | |
| Market (SPY) | -1.6% | 44.9% |
| Sector (XLV) | 13.7% | 38.1% |
Fundamental Drivers
The 32.8% change in CAI stock from 4/30/2026 to 11/8/2026 was primarily driven by a 29.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 11082026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.00 | 25.23 | 32.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 812 | 1,048 | 29.1% |
| P/S Multiple | 6.6 | 6.8 | 3.4% |
| Shares Outstanding (Mil) | 283 | 284 | -0.5% |
| Cumulative Contribution | 32.8% |
Market Drivers
4/30/2026 to 11/8/2026| Return | Correlation | |
|---|---|---|
| CAI | 32.8% | |
| Market (SPY) | 2.6% | 30.6% |
| Sector (XLV) | 27.1% | 31.2% |
Fundamental Drivers
The -16.1% change in CAI stock from 10/31/2025 to 11/8/2026 was primarily driven by a -10.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 11082026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.08 | 25.23 | -16.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 1,048 | 0.0% |
| Net Income Margin (%) | � | 9.2% | 0.0% |
| P/E Multiple | � | 74.6 | 0.0% |
| Shares Outstanding (Mil) | 255 | 284 | -10.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 11/8/2026| Return | Correlation | |
|---|---|---|
| CAI | -16.1% | |
| Market (SPY) | 8.7% | 35.3% |
| Sector (XLV) | 29.8% | 29.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/8/2026| Return | Correlation | |
|---|---|---|
| CAI | ||
| Market (SPY) | 81.9% | 31.8% |
| Sector (XLV) | 55.4% | 30.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CAI Return | 79% | 0% | 0% | 0% | -52% | -6% | -19% |
| Peers Return | -7% | 32% | 41% | -1% | 13% | 4% | 99% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| CAI Win Rate | 67% | 0% | 0% | 0% | 25% | 45% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 83% | 31% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| CAI Max Drawdown | -22% | 0% | 0% | 0% | -58% | -49% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ASPE, ATYR, BBTX, CTY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/6/2026 (YTD)
How Low Can It Go
| Event | CAI | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -62.4% | -33.7% |
| % Gain to Breakeven | 165.6% | 50.9% |
| Time to Breakeven | 217 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -12.9% | -19.2% |
| % Gain to Breakeven | 14.8% | 23.8% |
| Time to Breakeven | 2 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -13.7% | -3.7% |
| % Gain to Breakeven | 15.9% | 3.9% |
| Time to Breakeven | 7 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -62.8% | -12.2% |
| % Gain to Breakeven | 168.9% | 13.9% |
| Time to Breakeven | 341 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -74.5% | -6.8% |
| % Gain to Breakeven | 292.5% | 7.3% |
| Time to Breakeven | 438 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -20.0% | -0.2% |
| % Gain to Breakeven | 25.0% | 0.2% |
| Time to Breakeven | 27 days | 1 days |
In The Past
Caris Life Sciences's stock fell -62.4% during the 2020 COVID-19 Crash. Such a loss loss requires a 165.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CAI | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -62.4% | -33.7% |
| % Gain to Breakeven | 165.6% | 50.9% |
| Time to Breakeven | 217 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -62.8% | -12.2% |
| % Gain to Breakeven | 168.9% | 13.9% |
| Time to Breakeven | 341 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -74.5% | -6.8% |
| % Gain to Breakeven | 292.5% | 7.3% |
| Time to Breakeven | 438 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -37.2% | -17.9% |
| % Gain to Breakeven | 59.3% | 21.8% |
| Time to Breakeven | 107 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -21.2% | -15.4% |
| % Gain to Breakeven | 26.9% | 18.2% |
| Time to Breakeven | 31 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -79.6% | -53.4% |
| % Gain to Breakeven | 389.3% | 114.4% |
| Time to Breakeven | 404 days | 1085 days |
In The Past
Caris Life Sciences's stock fell -62.4% during the 2020 COVID-19 Crash. Such a loss loss requires a 165.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Caris Life Sciences (CAI)
CAI International, Inc. operates as a transportation finance and logistics company with a primary focus on acquiring, leasing, and managing intermodal containers and railcars globally. The company facilitates the movement of goods by providing essential equipment to the shipping and rail industries.
Its core business involves the leasing, re-leasing, and disposal of a diverse fleet of containers to major shipping lines, freight forwarders, and other transportation entities under various lease agreements. Beyond leasing, CAI also sells containers to investor groups, offering management services for these assets, and deals in used containers. By December 2014, its container fleet comprised over 1.1 million cost equivalent units.
In addition to containers, CAI International also owns and leases a fleet of various railcars in North America, serving railroad transport companies. This includes box cars for paper and forest products, covered hoppers for bulk commodities like grain and cement, general purpose tank cars for non-hazardous goods, gondolas for coal, and general service flat cars, further diversifying its equipment leasing portfolio.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
David Dean Halbert, Chairman, Founder and CEO
- Mr. Halbert is a proven leader with over 40 years of experience across the energy, financial, and healthcare industries.
- He founded AdvancePCS® in 1987, a pharmacy benefits management company, serving as Chairman and CEO until its sale to CareMark® in 2004 for $7.5 billion. Under his leadership, AdvancePCS grew into a publicly traded, Fortune® 250 corporation with over $15 billion in annual revenue and returned 31 times its initial public offering (IPO) value.
- He also grew Caris Diagnostics, which was sold to Miraca Life Sciences® in 2011 for $725 million.
- Mr. Halbert acquired Molecular Profiling Institute (MPI) in 2008, which became Caris Life Sciences.
- Mr. Power joined Caris Life Sciences in 2011 and has progressively held positions with increasing responsibility.
- He oversees finance, accounting, and audit operations, and provides strategic financial guidance for corporate operations and functions.
- Prior to joining Caris, Mr. Power worked within the PricewaterhouseCoopers (PWC) assurance practice in Ireland, the United States, and the United Kingdom.
- He is a Certified Public Accountant (CPA) and a fellow of Chartered Accountants Ireland, holding a degree in finance and accounting from Waterford Institute of Technology.
- Dr. Spetzler holds a PhD in mathematics and molecular cellular biology.
- Dr. Sledge serves as the Executive Vice President and Chief Medical Officer for Caris Life Sciences.
- Mr. Harmon serves as the Chief Operations Officer for Caris Life Sciences.
AI Analysis | Feedback
The background information provided describes CAI International, Inc., a transportation finance and logistics company. However, the request specifically asks for risks related to "Caris Life Sciences (symbol: CAI)". Publicly available information confirms that Caris Life Sciences currently trades under the symbol CAI on NASDAQ. Therefore, the provided background is not consistent with the company for which risks are requested.
As a precision medicine company utilizing AI and molecular profiling, Caris Life Sciences faces distinct risks compared to a transportation finance company. Key risks for Caris Life Sciences include:
- Competition and Market Acceptance of its Technology: Caris Life Sciences operates in the highly competitive and rapidly evolving field of precision medicine and molecular diagnostics. The company's success depends on the market acceptance and adoption of its proprietary molecular profiling platform and AI-driven solutions by healthcare providers, pharmaceutical companies, and patients. Intense competition from other diagnostic companies, large pharmaceutical firms, and academic institutions developing similar technologies could limit its growth and market share.
- Regulatory and Reimbursement Risks: The diagnostic and precision medicine industry is subject to extensive government regulation, including those from the FDA in the United States. Changes in regulatory requirements, delays in obtaining necessary approvals for new tests or platforms, or adverse regulatory decisions could significantly impact Caris Life Sciences' operations and product launches. Furthermore, securing adequate reimbursement from insurance providers and government programs for its advanced diagnostic tests is crucial for commercial success. Unfavorable changes in reimbursement policies or pricing pressures could negatively affect revenue and profitability.
- Reliance on Technology and Data Security: As an AI TechBio company, Caris Life Sciences heavily relies on its sophisticated technology, proprietary algorithms, and extensive genomic and molecular data. Risks include the potential for technological failures, cybersecurity breaches compromising sensitive patient data, or intellectual property infringement. Maintaining the integrity, security, and proprietary nature of its data and technology is paramount to its business model and competitive advantage.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Caris Life Sciences (NASDAQ: CAI) is poised for substantial revenue growth over the next two to three years, driven by several key initiatives and market trends. The company's forward guidance and recent earnings commentaries highlight a robust strategy focused on expanding its core services, launching innovative new products, and enhancing its commercial reach.
Here are the primary expected drivers of future revenue growth for Caris Life Sciences:
-
Expansion of Molecular Profiling Services: Caris Life Sciences anticipates continued strong growth in its molecular profiling services, particularly within its therapy selection segment. The company projects molecular profiling revenue to grow approximately 21% to 22% in 2026, or an estimated 26% to 28% excluding prior year adjustments. This growth is expected to be fueled by an approximate 20% year-over-year increase in clinical therapy selection volume. Additionally, improvements in average sales prices (ASPs) for both tissue and blood-based testing platforms are contributing to this expansion.
-
Launch and Adoption of Caris Detect: A significant driver of future revenue is the planned launch of Caris Detect, a multi-cancer early detection (MCED) test, in the first half of 2026. This new product is considered a major market opportunity with the potential to significantly impact cancer mortality rates. Interim results from the ACHIEVE-1 study support its upcoming launch, indicating promising clinical performance.
-
Aggressive Commercial Expansion and Sales Force Growth: To support the uptake of its existing and new products, Caris Life Sciences plans to aggressively invest in expanding its commercial organization. This includes plans to increase its sales force by approximately 20% to 25% to around 300 representatives in 2026. This strategic investment aims to drive greater adoption and market penetration of its comprehensive molecular profiling platform.
-
Growth in Pharmaceutical Research and Development (Pharma R&D) Services: While molecular profiling remains the core, the company also expects a recovery and growth in its pharmaceutical research and development services. For 2026, Pharma R&D services revenue is expected to be in the range of $75 million to $85 million. Collaborations, such as the announced partnership with Genentech for novel therapeutic target discovery, underscore the potential in this segment.
-
Leveraging AI TechBio Platform and Data Set: Caris Life Sciences positions itself as a next-generation AI TechBio company. Its extensive molecular data set, which has surpassed 1 million genomic profiles, serves as a valuable clinical genomic resource. This advanced platform, combining whole exome and whole transcriptome sequencing with AI and machine learning, is expected to attract more customers and strategic partnerships, fueling further growth in both its diagnostic and R&D offerings.
AI Analysis | Feedback
Share Issuance
- Caris Life Sciences completed its Initial Public Offering (IPO) on June 18, 2025, listing on the Nasdaq Global Select Market under the ticker symbol "CAI".
- The company priced its IPO at $21.00 per share, selling 23,529,412 shares of common stock and raising over $494.1 million.
- Caris Life Sciences granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price.
Inbound Investments
- In May 2021, Caris Life Sciences received an $830 million growth equity investment, which gave the company a post-money valuation of $7.83 billion.
- This 2021 investment round was led by Sixth Street, with significant participation from T. Rowe Price Associates Inc., Silver Lake, Fidelity Management & Research Co., and Coatue Management LLC.
- In April 2025, Caris Life Sciences closed a $168 million growth capital funding round, led by Braidwell LP, with participation from new investors Perceptive Advisors, Woodline, and Ghisallo, among others.
Capital Expenditures
- For the full year 2026, Caris Life Sciences anticipates capital expenditures to increase to $60 million.
- The primary focus of these expected capital expenditures in 2026 is for early detection capacity, including the purchase of additional NovaSeq X machines for their new Assure assay and early detection initiatives.
- As of December 31, 2025, Caris Life Sciences had over $800 million in cash on hand, providing strategic flexibility for ongoing investments in its technology platform for new products and the development of new channels like Multi-Cancer Early Detection (MCED).
Peer Outperformance in Biotechnology
CAI has outperformed 63% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that CAI has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
61%
of 452 industry peers · -1.5% return
3Y
40%
of 398 industry peers · -54.9% return
5Y
63%
of 364 industry peers · -54.9% return
No Biotechnology peer with a comparable growth profile has beaten CAI by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is CAI's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 6.4% | 56.1% | 94.3% | CAH 506% · MCK 394% · COR 179% |
| Health Care Services | 20 | 32.4% | 25.6% | 7.4% | HIMS 208% · RDNT 127% · DGX 98% |
| Managed Health Care | 8 | 55.2% | -1.8% | -2.7% | OSCR 86% · HQY 50% · ELV 7% |
| Health Care Facilities | 26 | 16.4% | 22.6% | -8.9% | THC 277% · NHC 227% · EHC 177% |
| Health Care Equipment | 50 | 4.0% | 18.3% | -16.3% | UFPT 356% · GKOS 318% · TMDX 175% |
| Pharmaceuticals | 60 | -8.6% | 18.7% | -39.8% | LQDA 933% · XERS 649% · KNSA 543% |
| Health Care Supplies | 11 | 23.1% | 19.5% | -41.3% | LNTH 242% · HAE 69% · MMSI 25% |
| Life Sciences Tools & Services | 108 | -6.4% | -14.5% | -74.1% | AXGN 249% · MEDP 191% · NTRA 166% |
| Biotechnology ← | 365 | -23.8% | -29.2% | -81.7% | ELVN 1232% · TRVI 1075% · DNTH 1069% |
| Health Care Technology | 21 | -21.7% | -47.8% | -83.1% | VEEV -5% · DOCS -54% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.87 |
| Mkt Cap | 73.7 |
| Rev LTM | 1,048 |
| Op Inc LTM | 140 |
| FCF LTM | 29 |
| FCF 3Y Avg | 836 |
| CFO LTM | 84 |
| CFO 3Y Avg | 1,066 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 36.0% |
| Rev Chg 3Y Avg | 10.3% |
| Rev Chg Q | 19.4% |
| QoQ Delta Rev Chg LTM | 2.9% |
| Op Inc Chg LTM | 274.2% |
| Op Inc Chg 3Y Avg | 768.4% |
| Op Mgn LTM | 13.4% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | -2.1% |
| CFO/Rev LTM | 8.0% |
| CFO/Rev 3Y Avg | 17.4% |
| FCF/Rev LTM | 2.8% |
| FCF/Rev 3Y Avg | 13.5% |
Price Behavior
Price Behavior
| Market Price | $25.23 | |
| Market Cap ($ Bil) | 8.7 | |
| First Trading Date | 05/16/2007 | |
| Distance from 52W High | -30.2% | |
| 50 Days | 200 Days | |
| DMA Price | $29.48 | $21.67 |
| DMA Trend | up | up |
| Distance from DMA | -14.4% | 16.4% |
| 3M | 1YR | |
| Volatility | 78.6% | 71.4% |
| Downside Capture | 172.63 | 166.13 |
| Upside Capture | 272.71 | 133.16 |
| Correlation (S&P 500) | 53.5% | 36.7% |
CAI Betas & Captures as of 10/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.20 | 1.98 | 1.62 | 1.01 | 1.49 | 0.41 |
| Up Beta | 7.19 | 3.98 | 1.16 | 0.95 | 1.77 | 0.29 |
| Down Beta | 2.43 | 2.20 | 2.75 | 1.86 | 1.62 | 0.07 |
| Up Capture | 315% | 304% | 408% | 152% | 150% | 22% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 13 | 24 | 33 | 63 | 122 | 163 |
| Down Capture | 90% | 13% | -144% | -19% | 122% | 97% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 9 | 19 | 31 | 62 | 127 | 178 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CAI | |
|---|---|---|---|---|
| CAI | -13.7% | 71.4% | 0.09 | - |
| Sector ETF (XLV) | 28.6% | 16.9% | 1.31 | 29.7% |
| Equity (SPY) | 9.5% | 13.6% | 0.40 | 36.4% |
| Gold (GLD) | 1.6% | 28.7% | 0.05 | 17.9% |
| Commodities (DBC) | 38.4% | 21.2% | 1.42 | -8.9% |
| Real Estate (VNQ) | 11.3% | 14.2% | 0.51 | 16.9% |
| Bitcoin (BTCUSD) | -27.2% | 43.6% | -0.61 | 21.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CAI | |
|---|---|---|---|---|
| CAI | -1.9% | 66.5% | 0.17 | - |
| Sector ETF (XLV) | 8.3% | 15.4% | 0.35 | 30.1% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 31.6% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 14.5% |
| Commodities (DBC) | 8.1% | 19.6% | 0.30 | -8.3% |
| Real Estate (VNQ) | 1.3% | 18.9% | -0.04 | 18.4% |
| Bitcoin (BTCUSD) | 4.0% | 51.6% | 0.26 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CAI | |
|---|---|---|---|---|
| CAI | 20.1% | 61.6% | 0.72 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.59 | 27.3% |
| Equity (SPY) | 15.0% | 18.0% | 0.70 | 34.4% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 2.7% |
| Commodities (DBC) | 7.5% | 18.1% | 0.33 | 13.1% |
| Real Estate (VNQ) | 5.9% | 20.7% | 0.24 | 26.6% |
| Bitcoin (BTCUSD) | 60.0% | 66.3% | 1.00 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 11/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2026 | -21.6% | ||
| 8/5/2026 | 21.6% | 35.3% | 53.9% |
| 5/7/2026 | -18.6% | -23.1% | -18.6% |
| 2/26/2026 | 4.7% | -0.1% | -11.9% |
| 11/5/2025 | -15.7% | -15.2% | -2.9% |
| 8/12/2025 | 5.6% | 13.8% | 5.4% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 2 |
| # Negative | 3 | 3 | 3 |
| Median Positive | 5.6% | 24.5% | 29.7% |
| Median Negative | -18.6% | -15.2% | -11.9% |
| Max Positive | 21.6% | 35.3% | 53.9% |
| Max Negative | -21.6% | -23.1% | -18.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2026 | -21.6% | ||
| 8/5/2026 | 21.6% | 35.3% | 53.9% |
| 5/7/2026 | -18.6% | -23.1% | -18.6% |
| 2/26/2026 | 4.7% | -0.1% | -11.9% |
| 11/5/2025 | -15.7% | -15.2% | -2.9% |
| 8/12/2025 | 5.6% | 13.8% | 5.4% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 2 |
| # Negative | 3 | 3 | 3 |
| Median Positive | 5.6% | 24.5% | 29.7% |
| Median Negative | -18.6% | -15.2% | -11.9% |
| Max Positive | 21.6% | 35.3% | 53.9% |
| Max Negative | -21.6% | -23.1% | -18.6% |
Recent Forward Guidance
Updated 11/5/2026Latest: Q3 2026 Earnings Reported 11/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Clinical Therapy Selection Volume Growth | Reported | 20.0% | 0.0% | Affirmed | Guidance: 20.0% for 2026 | |||
| 2026 Revenue | Reported | 1.04 Bil | 1.04 Bil | 1.05 Bil | 1.0% | Raised | Guidance: 1.03 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 28.0% | 28.5% | 29.0% | 1.0% | Raised | Guidance: 27.5% for 2026 | |
Prior: Q2 2026 Earnings Reported 8/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Clinical Therapy Selection Volume Growth | Reported | 20.0% | 0.0% | Affirmed | Guidance: 20.0% for 2026 | |||
| 2026 Revenue | Reported | 1.03 Bil | 1.03 Bil | 1.04 Bil | 2.5% | Raised | Guidance: 1.01 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 27.0% | 27.5% | 28.0% | 3.0% | Raised | Guidance: 24.5% for 2026 | |
Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Clinical Therapy Selection Volume Growth | Reported | 20.0% | 0 | Affirmed | Guidance: 20.0% for 2026 | |||
| 2026 Revenue | Reported | 1.00 Bil | 1.01 Bil | 1.02 Bil | 0 | Affirmed | Guidance: 1.01 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 23.0% | 24.5% | 26.0% | 0 | Affirmed | Guidance: 24.5% for 2026 | |
Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Clinical therapy selection volume growth | Reported | 20.0% | -1.5% | Lower New | Actual: 21.5% for 2025 | |||
| 2026 Revenue | Reported | 1.00 Bil | 1.01 Bil | 1.02 Bil | 39.3% | Higher New | Actual: 725.00 Mil for 2025 | |
| 2026 Revenue Growth | Reported | 23.0% | 24.5% | 26.0% | -51.5% | Lower New | Actual: 76.0% for 2025 | |
| 2026 Molecular profiling revenue growth | Reported | 21.0% | 21.5% | 22.0% | ||||
| 2026 Pharma & research revenue | Reported | 75.00 Mil | 80.00 Mil | 85.00 Mil | ||||
| 2026 Operating Expenses | Reported | 590.00 Mil | 592.50 Mil | 595.00 Mil | ||||
Insider Activity
Updated 9/23/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Denton, John Russel | See Remarks | Direct | Sell | 9232026 | 31.82 | 7,500 | 238,626 | 5,563,327 | Form |
| 2 | Brille, Brian J | See Remarks | Direct | Sell | 9172026 | 30.33 | 400,000 | 12,132,080 | 6,985,136 | Form |
| 3 | Spetzler, David Baxley | President | Direct | Sell | 9042026 | 24.76 | 119,212 | 2,951,117 | 29,282,208 | Form |
| 4 | Spetzler, David Baxley | President | Direct | Sell | 9042026 | 24.86 | 478,000 | 11,882,990 | 26,154,585 | Form |
| 5 | Halbert, Jon | LAH Investments, Ltd. | Buy | 7132026 | 14.56 | 68,000 | 990,080 | 10,258,947 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Denton, John Russel | See Remarks | Direct | Sell | 9232026 | 31.82 | 7,500 | 238,626 | 5,563,327 | Form |
| 2 | Brille, Brian J | See Remarks | Direct | Sell | 9172026 | 30.33 | 400,000 | 12,132,080 | 6,985,136 | Form |
| 3 | Spetzler, David Baxley | President | Direct | Sell | 9042026 | 24.76 | 119,212 | 2,951,117 | 29,282,208 | Form |
| 4 | Spetzler, David Baxley | President | Direct | Sell | 9042026 | 24.86 | 478,000 | 11,882,990 | 26,154,585 | Form |
| 5 | Halbert, Jon | LAH Investments, Ltd. | Buy | 7132026 | 14.56 | 68,000 | 990,080 | 10,258,947 | Form | |
| 6 | Vacirca, Jeff L | Direct | Buy | 5112026 | 16.15 | 31,050 | 501,426 | 802,137 | Form | |
| 7 | Power, Luke Thomas | See Remarks | Direct | Sell | 12122025 | 26.58 | 62,250 | 1,654,461 | 2,646,367 | Form |
| 8 | Denton, John Russel | See Remarks | Trust | Buy | 11102025 | 24.09 | 4,184 | 100,793 | 221,243 | Form |
| 9 | Spetzler, David Baxley | President | Direct | Buy | 11072025 | 23.85 | 400 | 9,540 | 10,989,531 | Form |
Investor Activity (13F)
Updated Nov 9, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 11/8/2026